J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Pharmaceutical Technology on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in US
Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Insider Monkey on MSN6d
Is Teva Pharmaceutical (TEVA) Trading at a Discount?
Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
GlobalData on MSN1d
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
BioPharma Dive1d
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara
Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...
Nasdaq4d
Teva Pharmaceuticals and Alvotech Announce U.S. Launch of SELARSDI™ Biosimilar for Multiple Indications
In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...